Navigation Links
Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Date:3/31/2009

mers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                Media
    info@peregrinei
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
6. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
7. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Va. The American Institute of Aeronautics and ... of top emerging aerospace technologies. Developed by ... the following: 1. "Greener Aviation" Technologies including ... in the Federal Aviation Administration,s Continuous Low Emissions, ...
... Multifaceted agreement enhances Microsoft Amalga Life Sciences to accelerate ... REDMOND, Wash., June 1 Microsoft Corp. today announced ... Co. Inc. to acquire certain assets of Rosetta Biosoftware, ... owned subsidiary of Merck & Co. Inc. The deal ...
... ... for Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference on ... Center. , ... PA (PRWEB) June 1, 2009 -- Genedata , a leading provider of in ...
Cached Biology Technology:AIAA names top ten emerging aerospace technologies of 2009 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... have conclusive evidence that the source of a unique ... and called the "bio-duck," is the Antarctic minke whale ... submarine personnel in the 1960s who thought it sounded ... at various locations in the Southern Ocean, but its ... February 2013, an international team of researchers deployed acoustic ...
(Date:4/23/2014)... At a signing ceremony in Buenos Aires yesterday, ... as an associate member state. The move strengthens ... life science communities. It grants Argentinian scientists access ... mutually beneficial collaborations. , "Ever since its inception, ... internationalisation have been at the core of EMBL,s ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... Sure, some delicacies might taste just like chicken, but they ... as the soy burger, have become more popular recently, with ... scientists at the University of Missouri have created a soy ... The new soy chicken also has health benefits, including lowering ...
... Researchers at the University of Pittsburgh and their ... to pursue the continued development of an implanted ventricular ... congenital or acquired heart disease. The project aims to ... saved the lives of older heart failure patients. ...
... scientists are reporting the first discovery of the female ... thought that only animals could make progesterone. A steroid ... for pregnancy and maintains pregnancy. A synthetic version, progestin, ... The discovery is reported in the American Chemical ...
Cached Biology News:It looks, feels and tastes like chicken, but it's made of soy 2Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 2Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 3